Virpax Cash Per Share from 2010 to 2025

VRPX Stock  USD 1.94  0.13  6.28%   
Virpax Pharmaceuticals Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share is likely to outpace its year average in 2025. During the period from 2010 to 2025, Virpax Pharmaceuticals Cash Per Share regression line of annual values had r-squared of  0.37 and arithmetic mean of  49.05. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
355.64496358
Current Value
373.43
Quarterly Volatility
123.49071332
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virpax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virpax Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Expense of 125.3 M or Selling General Administrative of 6.6 B, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Virpax financial statements analysis is a perfect complement when working with Virpax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Virpax Pharmaceuticals Correlation against competitors.
For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.

Latest Virpax Pharmaceuticals' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Virpax Pharmaceuticals over the last few years. It is Virpax Pharmaceuticals' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virpax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 2.22 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Virpax Cash Per Share Regression Statistics

Arithmetic Mean49.05
Geometric Mean0.19
Coefficient Of Variation251.76
Mean Deviation78.87
Median0.01
Standard Deviation123.49
Sample Variance15,250
Range373
R-Value0.61
Mean Square Error10,352
R-Squared0.37
Significance0.01
Slope15.70
Total Sum of Squares228,749

Virpax Cash Per Share History

2025 373.43
2024 355.64
2023 7.81
2022 16.22
2021 31.45
2020 0.11
2019 0.0796

About Virpax Pharmaceuticals Financial Statements

Virpax Pharmaceuticals investors use historical fundamental indicators, such as Virpax Pharmaceuticals' Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virpax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 355.64  373.43 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.